Dr Fieke Froeling is a Clinical Senior Lecturer at the University of Glasgow with an overall research focus on therapeutic development for pancreatic cancer. She trained as a Medical Oncologist and molecular biologist in London and New York, gaining experience in translating her research findings into clinical trials in both the UK and USA. She joined the University of Glasgow and CRUK Beatson Institute for Cancer Research in 2020 to start her translational research group. Using well-annotated patient samples and patient-derived pre-clinical model systems her research aims to understand the complex dynamics of tumour-host interactions in pancreatic cancer, and identify novel therapeutic approaches with candidate biomarkers that can be tested in clinical trials. She is the co-chief investigator and translational research lead of the second-line platform study for pancreatic cancer in the UK and leads the national molecular tumour board for pancreatic cancer patients enrolled in Precision-Panc, the national therapeutic development platform for pancreatic cancer in the UK. Clinically, she works as a Consultant Medical Oncologist at the Beatson West of Scotland Cancer and is the pancreatic cancer lead for the Glasgow Experimental Cancer Medicine Centre. Overall, this allows her to focus on developing personalised therapeutic strategies that emanate from discoveries in both basic science and reverse translation from clinical observation.